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Abstract
Background In clinical trials of medications to treat
attention-deficit/hyperactivity disorder (ADHD) in chil-
dren, effects on functional impairment have been less well-
studied than changes in ADHD symptoms.
Objective Data regarding functional impairment were
analyzed from a multicenter, double-blind, placebo-
controlled study of guanfacine extended release (GXR) in
children with ADHD, using the Weiss Functional Impair-
ment Rating Scale–Parent Report (WFIRS-P). The corre-
spondence of changes in WFIRS-P scores with
symptomatic and global response to GXR treatment was
also examined, with treatment response defined by scores
on both the ADHD Rating Scale IV (ADHD-RS-IV) and the
Clinical Global Impressions–Improvement Scale (CGI-I).
Methods In this 8-week, double-blind, placebo-
controlled, dose optimization study at 47 sites across the
USA and Canada, children aged 6–12 years with a diag-
nosis of ADHD [Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition, Text Revision criteria,
and an ADHD-RS-IV score C28 and CGI–Severity of
Illness Scale score C4 at baseline], were randomized 1:1:1
into three groups: GXR AM [GXR (1–4 mg/day) in the
morning, placebo in the evening], GXR PM [placebo in the
morning, GXR (1–4 mg/day) in the evening], or twice-
daily placebo. Parents rated their children on the WFIRS-P
at screening, baseline, the end of dose optimization, and at
the final on-treatment assessment.
Results The efficacy population was composed of
333 subjects (GXR AM: n = 107; GXR PM: n = 114; pla-
cebo: n = 112). At the final on-treatment assessment, there
were significant improvements from baseline in the pla-
cebo-adjusted difference in least-squares (LS) mean (95 %
confidence interval) WFIRS-P Total scores for both GXR
treatment groups combined [GXR all-active:-0.16 (-0.25,
-0.07), effect size (ES) = 0.448, P\0.001] and separately
[GXR AM: -0.15 (-0.26, -0.05), ES = 0.417, P = 0.004;
GXR PM: -0.18 (-0.28, -0.07), ES = 0.478, P = 0.001].
Significant improvements in WFIRS-P domain scores for
Family, Learning and School (including Academic Perfor-
mance and Behavior in School), Social, and Risky Behavior
were found for both GXR cohorts compared with placebo.
However, the Life Skills and Self-Concept domain scores of
the WFIRS-P did not improve with GXR treatment. Post
hoc stratification by responder status revealed that signifi-
cant (P\0.001) improvements in WFIRS-P Total and all
domain scores were associated with symptomatic treatment
response in the GXR all-active group.
Conclusions GXR treatment in children with ADHD was
associated with reductions in WFIRS-P functional impair-
ment scores compared with placebo, regardless of time of
GXR administration. Changes in WFIRS-P scores were
congruent with clinical response, as determined by both
ADHD symptom reduction and CGI-I scores.
ClinicalTrials.gov identifier NCT00997984.
& Mark A. Stein
mstein42@uw.edu
1 Psychiatry and Behavioral Medicine, Seattle Children’s
Hospital, 4800 Sand Point Way NE, Seattle, WA 98105, USA
2 GlaxoSmithKline, King of Prussia, PA, USA
3 Department of Psychiatry, University of British Columbia,
West Vancouver, BC, Canada
4 Neurovance, Inc., Cambridge, MA, USA
5 Independent statistician, Maidenhead, Berkshire, UK
6 Department of Psychiatry, Icahn School of Medicine at
Mount Sinai, New York, NY, USA
CNS Drugs (2015) 29:953–962
DOI 10.1007/s40263-015-0291-6
Key Points
The Weiss Functional Impairment Rating Scale–
Parent Report (WFIRS-P) provides specific
information regarding domains of functional
impairment in children with attention-deficit/
hyperactivity disorder (ADHD).
Guanfacine extended release (GXR) treatment was
associated with improvements in parent ratings of
their child’s ADHD-related functional impairment,
as measured by WFIRS-P, after 8 weeks of
treatment.
Improvements on the WFIRS-P were observed for
both morning and evening GXR administration.
Parent ratings of functional improvement on WFIRS-P
were generally congruent with symptomatic and
overall response to GXR treatment, as measured by
ADHD Rating Scale IV (ADHD-RS-IV) and
Clinical Global Impressions–Improvement Scale
(CGI-I) scores, respectively.
The Life Skills and Self-Concept domains of the
WFIRS-P did not improve with GXR treatment,
which may signal a need for longer trials, or
additional or more tailored psychosocial
interventions.
1 Introduction
Based on the 2011 US National Survey of Children’s
Health estimates, 11 % of surveyed parents reported that
their child (aged 4–17 years, median age 6.2 years) had
received a diagnosis of attention-deficit/hyperactivity dis-
order (ADHD) from a health care provider, with a current
prevalence of 8.8 % [1], making ADHD the most com-
monly diagnosed neurobehavioral disorder of childhood
[2]. ADHD is associated with impairments in adaptive
functioning and life skills, including problems with
socialization, communication, and activities of daily living
[3]. Although clinical trials in children with ADHD have
historically targeted ADHD symptoms, treatment-related
effects may also extend to improvements in functional
impairments, such as academic, social, and family func-
tioning, all of which are common reasons for children with
ADHD to be referred for treatment [4]. In a study of 314
children referred to an ADHD diagnostic clinic, ADHD
symptoms were only moderately correlated with global
impairment as measured by a composite Global
Impairment Index score, combining a number of parent-
and teacher-rated competency scales of behaviors observed
at home and school [5]. While it is presumed that symp-
tomatic improvement is generally associated with
improved functioning, more work is needed to better
understand the relationship between ADHD treatments,
changes in symptoms, and specific areas of functional
impairment.
The Weiss Functional Impairment Rating Scale–Parent
Report (WFIRS-P) is a brief, parent-reported questionnaire
developed specifically for children and adolescents with
ADHD. The WFIRS-P has been validated using data from
seven randomized controlled clinical studies [6]. Confir-
matory factor analyses established item-to-scale relation-
ships, with a root mean square error approximation\0.10,
the cut-off statistic for acceptable model fit; the confir-
matory fit index ranged from 0.80–0.88, which is below the
cut-off of 0.9 for acceptable model fit. Cronbach’s alpha
was[0.7 for all six domains, and test–retest reliability was
[0.7 for all domains other than Risky Activities (intra-
class correlation = 0.57). Mean changes in domain scores
were significantly different between responder and non-
responder groups in the hypothesized direction. These
results were also largely replicated in an independent val-
idation of a translated version of the WFIRS-P in Turkish
children [7], and other studies utilizing the WFIRS have
noted good reliability of the scale [8, 9]. The WFIRS-P has
been used to examine functional impairment in observa-
tional studies [10], treatment studies of psychoeducational
training [11], behavioral therapy in a summer treatment
program [11], and clinical trials of lisdexamfetamine
dimesylate (LDX) [12] and atomoxetine [13] pharma-
cotherapy. The WFIRS-P has demonstrated sensitivity in
evaluating domains of daily functioning often impaired in
ADHD, and in detecting treatment effects of ADHD
medications [12, 13]. In a recent study by Banaschewski
et al. [8], treatment with either LDX or osmotic-release oral
system–methylphenidate for 7 weeks had a positive impact
on functional impairment as measured by the WFIRS-P,
with significant placebo-adjusted improvements observed
in the Total score as well as in four of the six measured
domains (Learning and School, Family, Social Activities,
and Risky Activities). Furthermore, in a recent 9-week,
head-to-head study of LDX and atomoxetine in children
and adolescents with ADHD and an inadequate response to
methylphenidate [14], improvements in functional impair-
ment across all six domains were observed with both
treatments, with LDX showing superiority over atomox-
etine in the Total score as well as in two of the six domains
(Learning and School and Social Activities).
There are several non-stimulants that are approved for
use in ADHD. Guanfacine extended release (GXR) is a
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selective a2A-adrenoceptor agonist indicated for the treat-
ment of ADHD in the USA in children and adolescents
aged 6–17 years, both as monotherapy and adjunctive to
stimulant medications, and has received a positive opinion
from the Committee for Medicinal Products for Human use
in the European Union for the treatment of ADHD in
children and adolescents. The efficacy and safety of once-
daily morning administration of GXR has been established
in children and adolescents with ADHD in several ran-
domized, double-blind, placebo-controlled studies [15–18].
A recent study examined the efficacy and tolerability of
once-daily GXR monotherapy administered either in the
morning or evening in children aged 6–12 years with
ADHD in a randomized, double-blind, placebo-controlled
trial [18], and found that administration in either the
morning or evening resulted in significantly greater
reductions in ADHD symptoms compared with placebo, as
measured by the ADHD Rating Scale IV (ADHD-RS-IV),
which was the primary efficacy endpoint. The objective of
the current substudy (a secondary efficacy endpoint anal-
ysis) was to determine whether once-daily GXR
(1–4 mg/day) monotherapy, administered in the morning
or evening in children aged 6–12 years, impacts overall
functional impairment, as measured by the WFIRS-P [18].
An additional goal of this substudy was to examine the
effects of treatment on specific domains of functional
impairment. Finally, the relationship of functional impair-
ment to clinical improvement was examined in a post hoc
analysis of treatment responders versus non-responders by
stratifying WFIRS-P scores based upon treatment response
(defined by study endpoint scores on the ADHD-RS-IV and
the Clinical Global Impressions–Improvement Scale [CGI-
I], a physician-rated measure of global improvement).
2 Methods
2.1 Participants
Participants were aged 6–12 years with a primary diag-
nosis of ADHD (combined or hyperactive/impulsive sub-
type only) as defined by the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition, Text Revi-
sion, based upon the Kiddie-Schedule for Affective
Disorders and Schizophrenia–Present and Lifetime ver-
sion. In addition, subjects were required to have an
ADHD-RS-IV Total score C28 and a CGI–Severity of
Illness score C4 at baseline. Key exclusionary criteria
included the presence of any current controlled or
uncontrolled comorbid psychiatric diagnosis (except
oppositional defiant disorder), history of or current suicide
risk, and history of or current cardiac abnormalities or
primary sleep disorder.
2.2 Study Design
In this 8-week, randomized, double-blind, multicenter,
placebo-controlled dose optimization study, eligible sub-
jects were randomized 1:1:1 via an interactive web
response system to one of the following treatment arms:
GXR AM (GXR administered in the morning and placebo in
the evening), GXR PM (placebo administered in the
morning and GXR administered in the evening), or placebo
(placebo administered in the morning and evening) [18].
There was a 5-week dose-optimization period, a 3-week
dose-maintenance period, and a 9-day dose-taper period.
The starting dose of 1 mg/day was titrated upwards in
1-mg increments after a minimum of 1 week at the previ-
ous dose, based on clinical response and tolerability, up to
a maximum of 4 mg/day (Visits 2–7); optimal dose
response was defined as the dose which produced a C30 %
reduction in ADHD-RS-IV Total scores from baseline and
a CGI-I score of 1 or 2. After dose optimization, subjects
were maintained on their optimal dose for an additional
3 weeks, during which time efficacy and safety were
assessed weekly (Visits 8–10). The final on-treatment
timepoint was defined as the last non-missing, post-base-
line value while on treatment (before dose tapering) with
study drug [analogous to Visit 10, last observation carried
forward (LOCF)].
2.3 Assessments
The primary efficacy measure for the parent study was the
change from baseline in ADHD-RS-IV Total symptom
score; GXR treatment resulted in lower ratings of ADHD
symptoms and significant reductions in ADHD-RS-IV
Total scores [18]. This paper focuses on change in func-
tional status with treatment, as measured by the WFIRS-P
[19, 20].
The WFIRS-P consists of 50 items on which a parent or
guardian rates his/her child’s functioning; each question is
scored on a 4-point Likert scale [0 = ‘‘never or not at all’’
to 3 = ‘‘very often or very much’’; not applicable (NA) is
also an option], with higher scores reflecting higher levels
of functional impairment. Questions are grouped into six
domains: Family, Learning and School (divided into two
subdomains: Academic Performance and Behavior in
School), Life Skills, Self-Concept, Social Activities, and
Risky Activities. Total and domain/subdomain scores,
respectively, were the mean item scores across the whole
scale or in each domain/subdomain. The WFIRS-P has
been reported to have internal consistency and sensitivity
to change [6, 7, 19, 20], and shows positive correlations
with measures of ADHD symptoms and functioning [8].
In this study, the WFIRS-P was completed at screening
(Visit 1), baseline (Visit 2), the end of dose optimization
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(Visit 7), and final on-treatment assessment (Visit 10,
LOCF). WFIRS-P domain or Total scores were considered
invalid if[30 % of the item scores used for calculation at
baseline were missing or ‘‘NA’’ (with the exception of one
question relating to siblings, for which a score of NA could
contribute to the number of completed items); the number
of NA scores had no effect on the results of the overall
analyses since they were so few in number.
Safety evaluations, including assessments of adverse
events, vital signs, laboratory measures, and physical
examination findings, have been previously reported in
detail [18], and therefore are not discussed here.
2.4 Data Analyses
The pre-specified exploratory analysis was conducted on
all subjects who had taken C1 dose of study drug.
WFIRS-P analysis included change from baseline in
Total, domain, and subdomain scores at Visits 7 and 10,
and at final on-treatment assessment. Comparisons inclu-
ded GXR AM versus placebo, GXR PM versus placebo, and
both GXR groups combined (GXR all-active) versus
placebo. The study was not powered for comparisons
between GXR AM and GXR PM. Statistical analysis of the
WFIRS-P ratings was performed using an analysis of
covariance (ANCOVA) model. No adjustments were
made for multiplicity, and least-squares (LS) mean, effect
size, and P values were based on type III sum of squares
from an ANCOVA model for the change from baseline,
including treatment group as a fixed effect and baseline
value as a covariate. Effect sizes were measured using
Cohen’s d. Summaries and analyses were performed using
the LOCF method.
Functional impairment outcomes were also stratified
with response to treatment in a post hoc analysis. Mean
WFIRS-P scores were stratified by responder and non-re-
sponder status. Response was defined as a C30 % reduc-
tion in ADHD-RS-IV Total score from baseline and a CGI-
I score of 1 or 2 at final on-treatment assessment.
3 Results
3.1 Subject Disposition
A total of 340 subjects were enrolled; 333 subjects were
included in the analysis population. Of these, 221 subjects
were administered GXR [all-active group; 107 in the
morning (GXR AM), 114 in the evening (GXR PM)] and 112
were administered placebo. Subject demographic and
baseline characteristics were similar among treatment
groups, and have been described previously in detail [18].
The majority of subjects were male (70.6 %) and white
(57.1 %), and the mean age was 9.1 years (range
6–12 years). Among the analysis population, 96.1 % had
the combined subtype of ADHD, with a mean time since
original diagnosis of 1.7 years. A total of 247 subjects
completed the study through Visit 10 [80 (70.8 %) subjects
in the GXR AM group, 90 (78.9 %) subjects in the GXR PM
group, and 77 (68.1 %) subjects in the placebo group].
3.2 Weiss Functional Impairment Rating Scale–
Parent Report
At baseline, 107, 111, and 109 subjects had complete
WFIRS-P data from the GXR AM, GXR PM, and placebo
groups, respectively. Three subjects each in the GXR PM
and placebo groups from the full analysis set (all subjects
who had taken at least one dose of study drug) had missing
WFIRS-P data. Mean (standard deviation) baseline
WFIRS-P Total scores were similar between the treatment
groups: 0.876 (0.43) for GXR AM; 1.023 (0.49) for
GXR PM; and 0.998 (0.43) for placebo. At the final on-
treatment assessment, 97, 100, and 98 subjects had valid
WFIRS-P post-baseline data (prior to dose taper) from the
GXR AM, GXR PM, and placebo groups, respectively. At
the final on-treatment assessment, all GXR cohorts showed
significantly greater improvement from baseline in mean
WFIRS-P Total scores versus placebo (Table 1). Placebo-
adjusted differences in LS mean (95 % confidence interval)
were GXR AM: -0.15 (-0.26, -0.05), effect size = 0.417,
P = 0.004; GXR PM: –0.18 (-0.28, -0.07), effect
size = 0.478, P = 0.001; and GXR all-active: -0.16 (-
0.25, -0.07), effect size = 0.448, P\0.001.
Baseline WFIRS-P domain and subdomain scores were
similar for all treatment groups. However, at the final on-
treatment assessment, the mean change from baseline in
several WFIRS-P domain/subdomain scores was signifi-
cantly improved for all GXR cohorts compared with pla-
cebo (Fig. 1). These domains/subdomains included Family,
Learning and School (both Academic Performance and
Behavior in School subdomains), Social Activities, and
Risky Activities. The Life Skills domain scores were sig-
nificantly improved for the GXR all-active group versus
placebo at Visit 7, but not at the final on-treatment
assessment. Lastly, no significant differences were
observed between treatment arms for Self-Concept domain
scores.
3.3 Post Hoc Analyses
At the final on-treatment assessment, the percentage of
responders in the GXR AM (62.5 %), GXR PM (60.4 %),
and GXR all-active (61.4 %) groups was significantly
higher than placebo (30.9 %; P\0.001 for all compar-
isons). In a further post hoc analysis, a comparison was
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made on the WFIRS-P Total and domain scores for the
GXR all-active group responders versus the non-respon-
ders. At the final on-treatment assessment, GXR responders
demonstrated larger improvements versus non-responders
(P\0.001 for all scores; Fig. 2).
4 Discussion
Children with ADHD display a wide range of functional
problems above and beyond academic underachievement













































































































Fig. 1 LS mean change from
baseline in WFIRS-P scores at
Visit 10 (last observation
carried forward) for a GXR AM
[GXR (1–4 mg/day) in the
morning, placebo in the
evening], b GXR PM [placebo in
the morning, GXR
(1–4 mg/day) in the evening],
and c GXR all-active; full
analysis set. LS mean and
P values were based on type III
sum of squares from an analysis
of covariance model for the
change from baseline, including
treatment group as a fixed effect
and baseline value as a
covariate. A negative difference
in LS mean (GXR-placebo)
indicates a positive effect of the
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administration (morning or evening), resulted in significant
improvements in functional impairment as measured by the
WFIRS-P Total score, as well as the majority of domain
and subdomain scores. The observed effect size values
(Cohen’s d) for GXR AM (0.42) and GXR PM (0.48)
WFIRS-P Total scores were in the moderate range [21],
and slightly lower than those observed for ADHD symptom
improvement with GXR AM (0.75) and GXR PM (0.78)
[18]. Notably, improvements in family, school, social, and
risk scores were observed with GXR treatment whether
administered in the morning or evening (P\0.05 for both).
Within the Learning and School domain, subdomain scores
for both Academic Performance and Behavior in School
also significantly improved compared with placebo (effect
sizes ranged from 0.39–0.41 for the all-active group). The
effect sizes for these subdomain scores were expectedly
smaller than the treatment effect size seen when using the
WFIRS-P Total score, as the subdomain scores were based
on fewer WFIRS-P items. These results suggest that, on the
whole, treatment with GXR resulted in significant reduc-
tions in functional impairment after 8 weeks of treatment
when compared with placebo.
In contrast to the specific domains of impairment mea-
sured by the WFIRS-P that improved with treatment, both
the Life Skills and Self-Concept domain scores did not
differ from placebo at the final on-treatment assessment.
While the Life Skills domain scores significantly improved
for the GXR all-active group versus placebo at Visit 7, it
remains unclear why this improvement was not observed at
the final on-treatment assessment. These domains may be
less sensitive to measuring change, or require more inten-
sive or longer treatment for change to occur. It may also be
that Self-Concept in clinical trial subjects improves for all
regardless of treatment, given that these subjects often
receive support and encouragement from trial staff for
study participation and completion.
More research is needed to understand if improvement in
the above domains is particularly resistant to change or
measurement in a short-term trial. In a small single-center,
open-label, non-randomized study of children with ADHD
treated with atomoxetine (n = 21) [13], significant
improvement on the WFIRS-P Self-Concept domain was
not observed after 2 months of treatment. However,
improvement in Self-Concept was observed after 6 months
of treatment, and significant improvement in the Life Skills
domain was detected at both 2 and 6 months after treat-
ment; no significant improvements were observed in the
Social Activities and Risky Activities domains. Thus,
results from both the previous and current studies suggest
that the time course for treatment-related functional chan-
ges may vary across domains of impairment, and also in
relation to onset of symptom change. Perhaps the lack of
GXR treatment-related improvement on particular WFIRS-
P domains may signal the need for additional or more tai-
lored psychosocial interventions targeting specific life skills
and self-concept. It remains to be determined whether or not
the GXR-related improvements observed for all other
WFIRS-P domains would become larger with a treatment
period[8 weeks or if they would appear within the Life
Skills or Self-Concept domains; this requires further study.
Reductions in functional impairment were related to
symptomatic improvement and global response. Of note,
among responders, the degree of functional change reported
on the WFIRS-P was found to be comparable between those
on GXR and placebo. This suggests that perceived






































Fig. 2 Mean change from baseline in WFIRS-P scores at Visit 10
(last observation carried forward) by treatment response to GXR
treatment; full analysis set (GXR all-active group). Responders are
defined as subjects with ADHD-RS-IV Total score reduction from
baseline C30 % and a CGI-I score of 1 or 2. WFIRS-P Weiss
Functional Impairment Rating Scale–Parent Report, GXR guanfacine
extended release, ADHD-RS-IV Attention-Deficit/Hyperactivity
Disorder, CGI-I Clinical Global Impressions–Improvement Scale.
***P\0.001
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improvements in functional impairment regardless of the
intervention, and even whether active medication is
received. Among those on GXR, there was separation
between responders and non-responders, and the effect
sizes for improvement in WFIRS-P Total and domain
scores were in the moderate to large range. Nevertheless,
the effect size for functional improvement, even where
demonstrated, was lower than that for ADHD symptoms.
This difference is not surprising given that pharmacologic
treatments are specifically targeted to improve symptoms;
improvements observed in functional outcomes are a wel-
come secondary development, but are not necessarily
expected. Moreover, given that function is a more distal
concept, and that the inclusion/exclusion criteria of the
current trial were created to identify subjects with ADHD
symptoms and not functional impairment, it is expected that
there will be a lesser impact on function in this population.
What is remarkable is the strength of functional impairment
that does occur in multiple studies and in most (but not all)
domains. The fact that some domains do not improve with
treatment suggests that when improvement does occur, it is
not simply a function of the correlation between symptom
measures and functional measures. It is possible that func-
tional impairment in some areas improves more with other
forms of treatment (e.g., psychosocial [11, 22]), whereas
symptoms of ADHD may decrease more substantially with
psychopharmacologic interventions. Regardless, both
symptom and impairment measures are important outcomes
for treatment and, although correlated, are not the same.
The results of the current study are similar to those obtained
by Hervas et al. [23] in a recent phase III study of dose-opti-
mized GXR treatment in children and adolescents with
ADHD,which found that subjects onGXR showed significant
placebo-adjusted improvements in both the WFIRS-P
Learning and School domain and Family domain (study key
secondary endpoints) at the last on-treatment study visit prior
to dose tapering (effect sizes = 0.42 and 0.38 for each
domain, respectively). Also, comparatively larger magnitude
placebo-adjusted improvements on the WFIRS-P have been
shown in subjects with ADHD after treatment with the stim-
ulant LDX (effect size forWFIRS-PTotal score = 0.924) [8].
These prior findings, in combination with those of the current
study, suggest that treatment with both non-stimulants and
stimulants has a significant impact on functional impairment
outcomes, as measured by the WFIRS-P.
The clinical relevance of identifying and targeting
functional impairment is substantial. At home, ADHD may
negatively impact a child’s ability to follow family routi-
nes, straining relationships with parents and siblings [24,
25]. At school, children with ADHD are more likely to
display academic difficulties than those without ADHD
[26], and these difficulties are associated with decreased
academic achievement and decreased vocational
achievement later in life [27, 28]. Recent evidence using a
large registry database also highlighted an increased inci-
dence of accidental injury among children with ADHD; in
children treated with ADHD drugs compared with matched
untreated children, the prevalence of injuries was reduced
by 31.5 % at age 10 years and 43.5 % at age 12 years [29].
Results from this study further suggest that treatment-
related improvements may extend beyond core symptoms
to include improvements in functional impairment, which
presumably may lead to improved academic performance,
better parent–child relationships, and decreased incidence
of accidental injury. It remains to be seen, however, if the
improvements seen in short-term trials, such as the current
one, can persist and be maintained in the longer term.
A number of study limitations should be noted. First, both
the WFIRS-P and ADHD symptoms measures are largely
based on parent report. Because they are observational only,
the ratings may be subject to parental bias compared with
more objective measures (e.g., grades, number of play
dates). In addition, because both scales are completed by the
same rater, there is potential for confounding; it would be
important to determine if parent ratings of functional
improvement are in agreement with scales completed by
other informants, such as teachers. However, parent reports
often drive referral for treatment, and identifying parent-
reported improvement in functional status via the WFIRS-P
represents some reassurance that improvement in symptoms
translates to functional status; in this sense, using a measure
of functional status together with traditional measures of
symptomatic and overall response represents a step forward.
Another limitation is that this study was not adequately
powered to directly compare the GXR AM and GXR PM
groups, and the statistical tests conducted were not corrected
for multiple comparisons, allowing for the possibility of
type I error. Third, the subjects predominately had com-
bined type ADHD with moderate to severe symptom bur-
den, which may limit the generalizability of the study results
to children with less severe ADHD or those with the pre-
dominantly inattentive presentation. Finally, while these
results suggest a significant relationship between improve-
ments in symptoms and improvements in functional
impairment, future research should more precisely examine
the relationship between symptomatic and functional
domains, i.e., whether symptom change mediates improve-
ment in functional status, and whether there are baseline
factors that moderate these relationships.
5 Conclusions
Once-daily GXR monotherapy administered in the morning
or evening was associated with reductions in functional
impairment in children with ADHD, as assessed by the
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WFIRS-P scale. Improvements were seen across multiple
domains and subdomains of the WFIRS-P. Functional
improvements generally corresponded to improvements in
symptoms. Children who were treatment responders were
more likely to show significant functional improvements
than non-responders.
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